Side-by-side · Research reference
HGH 191AAvsPinealon
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedHUMAN-REVIEWED0/75 cited
BHuman-MechanisticAUTO-DRAFTED12/36 cited
HGH 191AA
Recombinant hGH · FDA-Approved
0.024–0.034 mg/kg/dayPediatric GHD dose
2–4 hoursPlasma half-life
191 AASequence length
SQ · Daily · Evening preferred
Pinealon
Pineal-derived · Neuroprotective
SQ or IM · Daily for 10 days · 1-2×/year
01Mechanism of Action
Parameter
HGH 191AA
Pinealon
Primary target
Growth hormone receptor (GHR) — JAK2/STAT5 pathway
Antioxidant defense + neuronal gene expression (proposed)Khavinson 2014
Pathway
GHR activation → JAK2/STAT5 → liver IGF-1 synthesis + direct metabolic effects
Modulation of antioxidant enzymes (SOD, catalase) + neurotrophic factor expressionKhavinson 2014
Downstream effect
Linear growth, lipolysis, protein synthesis, nitrogen retention, carbohydrate metabolism modulation
Reduced oxidative stress in neurons; improved cognitive function in age-related declineKhavinson 2014
Feedback intact?
No — exogenous GH bypasses hypothalamic-pituitary axis, suppresses endogenous pulsatility
—
Origin
Recombinant DNA technology — 191 AA, identical to pituitary hGH, no methionyl residue
Synthetic 4-AA peptide derived from pineal gland extractKhavinson 2014
Antibody development
Rare — <2% develop binding antibodies, typically non-neutralizing
—
02Dosage Protocols
Parameter
HGH 191AA
Pinealon
Pediatric GHD
0.024–0.034 mg/kg/day SQ
6–7× per week dosing typical. Brand-specific ranges.
—
Adult GHD
0.004–0.016 mg/kg/day SQ
Start low, titrate based on IGF-1 levels.
—
Turner syndrome
0.045–0.050 mg/kg/day SQ
—
Idiopathic short stature
0.037 mg/kg/day SQ
—
AIDS wasting
0.1 mg/kg/day SQ (high-dose)
Short-term indication. Monitor glucose.
—
Frequency
Once daily, typically evening
Evening administration mimics physiological GH pulse.
Once daily during cycle
Monitoring
IGF-1, glucose, thyroid function, bone age (children)
—
Duration
Years (children until epiphyseal closure); indefinite (adult GHD)
10-day cycles, 1–2× per year
Lower / starter dose
—
2.5 mg / day
Reconstitution
—
Bacteriostatic water
Timing
—
No specific time
Half-life
—
Hours
03Metabolic / Fat Loss Evidence
Parameter
HGH 191AA
Pinealon
Primary fat target
Visceral and subcutaneous adipose tissue
—
Mechanism
Lipolysis via hormone-sensitive lipase activation, FFA oxidation
—
Effect on lean mass
Significant lean mass increase (protein synthesis, nitrogen retention)
—
Insulin sensitivity
Acute insulin resistance (anti-insulin effect); chronic neutral-to-improved via fat loss
—
IGF-1 elevation
Dose-dependent, significant — primary anabolic mediator
—
Glucose metabolism
Hyperglycemia risk, especially high doses (AIDS wasting)
—
Body composition
↓ fat mass, ↑ lean mass, ↑ bone mineral density (children)
—
Clinical context
FDA-approved for AIDS wasting (cachexia). Off-label use for body recomposition lacks long-term safety data.
—
04Side Effects & Safety
Parameter
HGH 191AA
Pinealon
Injection site reaction
Lipohypertrophy, lipoatrophy, erythema (rotate sites)
Mild irritation
Fluid retention / Edema
Peripheral edema, arthralgia, carpal tunnel syndrome (dose-dependent)
—
Glucose intolerance
Hyperglycemia, new-onset diabetes (anti-insulin effect)
—
Intracranial hypertension
Benign intracranial hypertension (pseudotumor cerebri) — headache, visual changes, papilledema
—
Slipped capital femoral epiphysis
SCFE risk in children — limp, hip/knee pain (requires surgery)
—
Scoliosis progression
Rapid growth may unmask/progress scoliosis (monitor spine in children)
—
Hypothyroidism
Central hypothyroidism unmasking or worsening (monitor TSH, free T4)
—
Cancer risk
Contraindicated in active malignancy. Theoretical risk in cancer survivors (controversial).
—
Antibody formation
Rare (<2%), typically non-neutralizing. Loss of efficacy if neutralizing antibodies develop.
—
Pancreatitis
Rare. Higher risk in children with certain syndromes (Prader-Willi).
—
Gynecomastia
Adolescent males (physiological during puberty, may be exacerbated)
—
Long-term safety
—
Limited Western data
Pregnancy / OB
—
Avoid
Absolute Contraindications
HGH 191AA
- ·Active malignancy or history of cancer (especially childhood cancer survivors with risk factors)
- ·Acute critical illness (post-cardiac surgery, trauma, acute respiratory failure)
- ·Diabetic retinopathy (active proliferative or severe non-proliferative)
- ·Prader-Willi syndrome with severe obesity, sleep apnea, or respiratory impairment
- ·Closed epiphyses (for growth indications)
Pinealon
- ·Pregnancy / breastfeeding
Relative Contraindications
HGH 191AA
- ·Diabetes mellitus (monitor closely, may require insulin adjustment)
- ·Intracranial lesions or history of intracranial hypertension
- ·Scoliosis (monitor curve progression)
- ·Untreated hypothyroidism (treat before GH initiation)
- ·Severe obesity (assess OSA risk, cardiovascular status)
Pinealon
- ·Active malignancy (theoretical via gene expression modulation)
05Administration Protocol
Parameter
HGH 191AA
Pinealon
1. Reconstitution (if lyophilized)
Add diluent (sterile water or bacteriostatic water per manufacturer) to vial. Swirl gently — do not shake. Solution should be clear, colorless. Concentration varies by brand (e.g., 5 mg or 10 mg per vial).
Add 1–2 mL bacteriostatic water to 10 mg vial.
2. Injection site
Subcutaneous — rotate sites: abdomen, thigh, buttocks, upper arm. Avoid same site within 1 cm for 2 weeks to prevent lipodystrophy.
SQ — abdomen preferred.
3. Timing
Once daily, evening preferred (6–8 PM or pre-sleep). Mimics physiological nocturnal GH secretion. Consistency is critical.
Daily during cycle, any time.
4. Storage
Unreconstituted: refrigerate 2–8 °C, protect from light. Reconstituted: refrigerate, use within 14–28 days (brand-specific). Do not freeze.
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
5. Needle
27–31G, 4–8 mm insulin syringe or pen device. Pinch skin, 45–90° angle depending on subcutaneous thickness.
29–31G, 4–8 mm insulin syringe.
6. Monitoring
Baseline and periodic: IGF-1 (target age/sex-adjusted midrange), fasting glucose, HbA1c, thyroid function (TSH, free T4), bone age (children), lipid panel. Fundoscopy if headache/visual symptoms.
—
06Stack Synergy
HGH 191AA
+ Ipamorelin
ModerateIpamorelin (GHRP) stimulates endogenous GH release, which is redundant when exogenous rhGH is administered. However, ipamorelin may still amplify pulsatility of remaining endogenous secretion in partial GHD or during GH dose titration. Not typically combined in standard clinical practice; more common in experimental or off-label protocols. Limited evidence for additive benefit.
- HGH 191AA
- Standard dose per indication
- Ipamorelin
- 100–200 mcg SQ · morning (if used)
- Note
- Monitor IGF-1 closely; avoid supraphysiological levels
- Primary benefit
- Theoretical enhancement of pulsatility; limited clinical rationale
+ Tesamorelin
WeakTesamorelin (GHRH analogue) stimulates endogenous GH secretion, which is unnecessary when exogenous rhGH is already provided. Combining both offers no mechanistic advantage and increases cost, side effects, and IGF-1 elevation risk. Not recommended in clinical practice.
- Note
- Combination not recommended — choose one GH modality
- Primary benefit
- None — redundant mechanisms
Pinealon
+ Epitalon
ModeratePinealon (neuroprotection) + Epitalon (telomerase activation) form the canonical Khavinson "longevity stack" — both pineal-derived bioregulators with complementary axes. Pinealon supports neuronal antioxidant defense; Epitalon supports telomere maintenance. Anecdotally cycled together 1–2× per year.
- Pinealon
- 5–10 mg SQ · daily × 10 days
- Epitalon
- 5–10 mg SQ · daily × 10 days (overlap or alternate)
- Primary benefit
- Neuroprotection + telomere preservation